Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly

September 03, 2025 at 09:30 AM EDT

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ). This fund provides investors with amplified 2X inverse daily exposure to the performance of Eli Lilly and Company (NYSE: LLY), enabling retail investors to seek enhanced downside exposure without the need for a margin account.

LLYZ seeks to deliver daily investment results, before fees and expenses, of -200% of the daily performance of Eli Lilly and Company. The Fund utilizes derivatives such as swaps and options to achieve its leveraged objectives, offering precise exposure to this issuer.

Why Eli Lilly?
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical leader known for innovative therapies in diabetes, oncology, immunology, and neuroscience.

LLYZ offers targeted inverse exposure for traders seeking amplified downside exposure without the need for a margin account.

An investment in LLYZ is not an investment in Eli Lilly and Company.

The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged inverse (-2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. For periods longer than a single day, the Fund will lose money if the Underlying Security's performance is flat, and it is possible that the Fund will lose money even if the Underlying Security's performance declines over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day.

About Defiance
Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account.

IMPORTANT DISCLOSURES
The Fund's investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read carefully before investing. A hard copy of the prospectuses can be requested by calling 833.333.9383.

Defiance ETFs LLC is the ETF sponsor. The Fund's investment adviser is Tidal Investments, LLC ("Tidal" or the "Adviser").

Investing involves risk. Principal loss is possible. As an ETF, the fund may trade at a premium or discount to NAV. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. A portfolio concentrated in a single industry or country may be subject to a higher degree of risk.

There is no guarantee that the Fund's investment strategy will be properly implemented, and an investor may lose some or all of its investment.

Underlying Security Risk. The underlying security is subject to many risks that can negatively impact the Fund.

Underlying Securities Trading Risk. The trading prices of LLY may be highly volatile and subject to wide fluctuations in response to various factors.

Underlying Securities Performance Risk. Eli Lilly and Company may fail to meet expectations, which could cause its share price to decline.

Pharmaceutical Industry Risk. The pharmaceutical industry can be significantly affected by regulatory approvals, clinical trial outcomes, competitive dynamics, safety concerns, and pricing pressures.

Derivatives Risks. Derivative investments may not perfectly track the underlying security and can magnify losses.

Swap Agreements and Options Contracts. These instruments involve specialized risks that can prevent the Fund from achieving its objectives.

Leverage Risk. Leverage increases risk of loss and volatility in Fund value.

Compounding Risk. The Fund has a single-day investment objective, and compounding can cause multi-day returns to diverge significantly from the stated daily target.

Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally.

Liquidity Risk. Some securities held by the Fund may be difficult to sell or be illiquid, particularly during times of market turmoil.

High Portfolio Turnover Risk. Frequent trading may increase costs and tax liabilities.

Non-Diversification & Single Issuer Risk. The Fund invests primarily in a single issuer, making it more volatile than diversified funds.

New Fund Risk. The Fund has no operating history, limiting performance assessment.

Brokerage commissions may be charged on trades.

Distributed by Foreside Fund Services, LLC.

David Hanono

info@defianceetfs.com

833.333.9383

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/3a4cecbe-a064-4712-9393-861cf62effb5